GLP-1 receptor agonists in Parkinsons disease: an updated comprehensive systematic review with meta-analysis
A phase 2, double-blind, placebo-controlled trial randomized patients with moderate-severe PDPN to subcutaneous fulranumab or placebo
NAD+ is not a peptide , it is a dinucleotide coenzyme , more similar to ATP and other nucleotides than to amino-acid chains
View Study Organ Targets Powered by Human Organ Atlas Organs and body systems affected by DSIP (Delta Sleep-Inducing Peptide), mapped to the Human Organ Atlas an open-access 3D portal featuring 56 organs imaged at near-cellular resolution
Pre-Research Assessment: Complete medical history and physical review Baseline blood glucose and HbA1c Liver function tests (ALT, AST, bilirubin) Renal function tests (creatinine, BUN, eGFR) Complete blood count Lipid panel IGF-1 and IGFBP-3 levels Thyroid function tests Screening for contraindications During Research Tracking: Regular blood glucose tracking (frequency based on dose and risk factors) Periodic assessment of liver and renal function Tracking for signs of fluid retention Assessment of injection sites Records of any adverse findings Regular evaluation of research parameters Post-Research Assessment: Repeat baseline laboratory tests Evaluation of any persistent effects Assessment of research outcomes Planning of appropriate follow-up Managing Adverse Observations Research protocols should include plans for managing possible adverse findings
